Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer
It has been widely acknowledged that the use of immune checkpoint inhibitors (ICI) is an effective therapeutic treatment in many late-stage cancers. However, not all patients could benefit from ICI therapy. Several biomarkers, such as high expression of PD-L1, high mutational burden, and higher numb...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-08-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2022.948405/full |
| _version_ | 1811319967572819968 |
|---|---|
| author | Ofek Mussafi Ofek Mussafi Jie Mei Wenjun Mao Yuan Wan |
| author_facet | Ofek Mussafi Ofek Mussafi Jie Mei Wenjun Mao Yuan Wan |
| author_sort | Ofek Mussafi |
| collection | DOAJ |
| description | It has been widely acknowledged that the use of immune checkpoint inhibitors (ICI) is an effective therapeutic treatment in many late-stage cancers. However, not all patients could benefit from ICI therapy. Several biomarkers, such as high expression of PD-L1, high mutational burden, and higher number of tumor infiltration lymphocytes have shown to predict clinical benefit from immune checkpoint therapies. One approach using ICI in combination with other immunotherapies and targeted therapies is now being investigated to enhance the efficacy of ICI alone. In this review, we summarized the use of other promising immunotherapies and targeted therapies in combination with ICI in treatment of lung cancers. The results from multiple animals and clinical trials were reviewed. We also briefly discussed the possible outlooks for future treatment. |
| first_indexed | 2024-04-13T12:51:30Z |
| format | Article |
| id | doaj.art-b3c759419e8a4be4ba5553a81c545931 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-13T12:51:30Z |
| publishDate | 2022-08-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-b3c759419e8a4be4ba5553a81c5459312022-12-22T02:46:12ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2022-08-011210.3389/fonc.2022.948405948405Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancerOfek Mussafi0Ofek Mussafi1Jie Mei2Wenjun Mao3Yuan Wan4Department of Cardiothoracic Surgery, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi, ChinaThe Pq Laboratory of BiomeDx/Rx, Department of Biomedical Engineering, Binghamton University-SUNY, Binghamton, NY, United StatesDepartment of Oncology, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi, ChinaDepartment of Cardiothoracic Surgery, The Affiliated Wuxi People’s Hospital of Nanjing Medical University, Wuxi, ChinaThe Pq Laboratory of BiomeDx/Rx, Department of Biomedical Engineering, Binghamton University-SUNY, Binghamton, NY, United StatesIt has been widely acknowledged that the use of immune checkpoint inhibitors (ICI) is an effective therapeutic treatment in many late-stage cancers. However, not all patients could benefit from ICI therapy. Several biomarkers, such as high expression of PD-L1, high mutational burden, and higher number of tumor infiltration lymphocytes have shown to predict clinical benefit from immune checkpoint therapies. One approach using ICI in combination with other immunotherapies and targeted therapies is now being investigated to enhance the efficacy of ICI alone. In this review, we summarized the use of other promising immunotherapies and targeted therapies in combination with ICI in treatment of lung cancers. The results from multiple animals and clinical trials were reviewed. We also briefly discussed the possible outlooks for future treatment.https://www.frontiersin.org/articles/10.3389/fonc.2022.948405/fullimmunotherapyPD-1PD-L1immune checkpoint inhibitorlung cancer |
| spellingShingle | Ofek Mussafi Ofek Mussafi Jie Mei Wenjun Mao Yuan Wan Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer Frontiers in Oncology immunotherapy PD-1 PD-L1 immune checkpoint inhibitor lung cancer |
| title | Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer |
| title_full | Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer |
| title_fullStr | Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer |
| title_full_unstemmed | Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer |
| title_short | Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer |
| title_sort | immune checkpoint inhibitors for pd 1 pd l1 axis in combination with other immunotherapies and targeted therapies for non small cell lung cancer |
| topic | immunotherapy PD-1 PD-L1 immune checkpoint inhibitor lung cancer |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2022.948405/full |
| work_keys_str_mv | AT ofekmussafi immunecheckpointinhibitorsforpd1pdl1axisincombinationwithotherimmunotherapiesandtargetedtherapiesfornonsmallcelllungcancer AT ofekmussafi immunecheckpointinhibitorsforpd1pdl1axisincombinationwithotherimmunotherapiesandtargetedtherapiesfornonsmallcelllungcancer AT jiemei immunecheckpointinhibitorsforpd1pdl1axisincombinationwithotherimmunotherapiesandtargetedtherapiesfornonsmallcelllungcancer AT wenjunmao immunecheckpointinhibitorsforpd1pdl1axisincombinationwithotherimmunotherapiesandtargetedtherapiesfornonsmallcelllungcancer AT yuanwan immunecheckpointinhibitorsforpd1pdl1axisincombinationwithotherimmunotherapiesandtargetedtherapiesfornonsmallcelllungcancer |